Clinical impact of in vitro cellular drug resistance on childhood acute lymphoblastic leukemia in Taiwan

References

• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166–178.
   PubMed Web of Science ®Google Scholar
• Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 2007;6:149–165.
   PubMed Web of Science ®Google Scholar
• Lugthart S, Cheok MH, den Boer ML, . Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005;7: 375–386.
   PubMed Web of Science ®Google Scholar
• Pieters R, Klumper E, Kaspers GJ, . Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol 1997;25:11–26.
   PubMed Web of Science ®Google Scholar
• Den Boer ML, Harms DO, Pieters R, . Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21:3262–3268.
   PubMed Web of Science ®Google Scholar
• Hongo T, Yajima S, Sakurai M, . In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997;89:2959–2965.
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Veerman AJ, Pieters R, . In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723–2729.
   PubMed Web of Science ®Google Scholar
• Pieters R, den Boer ML, Durian M, . Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia—implications for treatment of infants. Leukemia 1998;12:1344–1348.
   PubMed Web of Science ®Google Scholar
• Hongo T, Okada S, Inoue N, . Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing. Int J Hematol 2002;76:251–259.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia—current status and future perspectives. Lancet Oncol 2001;2:597–607.
   PubMed Web of Science ®Google Scholar
• Dordelmann M, Reiter A, Borkhardt A, . Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999;94:1209–1217.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Ludwig WD, . Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310–3322.
   PubMed Web of Science ®Google Scholar
• Appel IM, Kazemier KM, Boos J, . Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia 2008;22:1665–1679.
   PubMed Web of Science ®Google Scholar
• Escherich G, Troeger AF, Gobel U, . The long-term impact of in vitro drug sensitivity testing on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL06 - 97). Haematologica 2011;96:854–862.
   PubMed Web of Science ®Google Scholar
• Chen SH, Yang CP, Hung IJ, . Clinical features, molecular diagnosis, and treatment outcome of infants with leukemia in Taiwan. Pediatr Blood Cancer 2010;55:1264–1271.
   PubMed Web of Science ®Google Scholar
• Liang DC, Shih LY, Yang CP, . Multiplex RT-PCR assay for the detection of major fusion transcripts in Taiwanese children with B-lineage acute lymphoblastic leukemia. Med Pediatr Oncol 2002;39:12–17.
   PubMedGoogle Scholar
• Lin WY, Liu HC, Yeh TC, . Triple intrathecal therapy without cranial irradiation for central nervous system preventive therapy in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50:523–527.
   PubMed Web of Science ®Google Scholar
• Liang DC, Yang CP, Lin DT, . Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:397–405.
   PubMed Web of Science ®Google Scholar
• Chen SH, Yang W, Fan Y, . A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia 2011;25:66–74.
   PubMed Web of Science ®Google Scholar
• D'Argenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles, CA: Biomedical Simulations Resource; 1997.
   Google Scholar
• Chessells JM, Richards SM, Bailey CC, . Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol 1995;89:364–372.
   PubMed Web of Science ®Google Scholar
• Shuster JJ, Wacker P, Pullen J, . Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 1998;16:2854–2863.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Mone SM, . Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738–1743.
   PubMed Web of Science ®Google Scholar
• Moricke A, Zimmermann M, Reiter A, . Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265–284.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Stevenson KE, O'Brien JE, . Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985 - 2000). Leukemia 2010;24:320–334.
   PubMed Web of Science ®Google Scholar
• Conter V, Arico M, Basso G, . Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:255–264.
   PubMed Web of Science ®Google Scholar
• Ramakers-van Woerden NL, Pieters R, Hoelzer D, . In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol 2002;38:379–386.
   PubMedGoogle Scholar
• Frost BM, Nygren P, Gustafsson G, . Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003;122:376–385.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Arico M, Harbott J, . Philadelphia chromosome-positive (Ph +) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998;92:2730–2741.
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Ludwig WD, . Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122–3133.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Pei D, . Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360:2730–2741.
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Pieters R, Van Zantwijk CH, . Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998;92:259–266.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Wysocki M. Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 2004;22:963–964.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Sancho J, Hancock ML, . Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691–2696.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Sancho J, Behm FG, . Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100:52–58.
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Devidas M, Hunger SP, . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008;111:5477–5485.
   PubMed Web of Science ®Google Scholar
• Stow P, Key L, Chen X, . Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010;115:4657–4663.
   PubMed Web of Science ®Google Scholar
• Iwamoto S, Mihara K, Downing JR, . Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049–1057.
   PubMed Web of Science ®Google Scholar
• De Haas V, Kaspers GJ, Oosten L, . Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia? Br J Haematol 2002;118:1190–1191.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Nyvold C, Seyfarth J, . Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. Leukemia 2001;15:1066–1071.
   PubMed Web of Science ®Google Scholar
• Galderisi F, Stork L, Li J, . Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia. Pediatr Blood Cancer 2009;53:543–550.
   PubMed Web of Science ®Google Scholar
• Lonnerholm G, Thorn I, Sundstrom C, . In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia. Leuk Res 2009;33:46–53.
   PubMed Web of Science ®Google Scholar